Merck & Co (NY: MRK )

115.25 +0.54 (+0.47%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,331,098
Open 114.47
Bid (Size) 114.09 (1)
Ask (Size) 115.25 (29)
Prev. Close 114.71
Today's Range 114.04 - 115.50
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
The company is adding onto its success outperforming Merck's top drug in lung cancer patients. 
Via Investor's Business Daily
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
+1.77%
+1.77%
1 Month
+0.75%
+0.75%
3 Month
-10.91%
-10.91%
6 Month
-4.36%
-4.36%
1 Year
+6.90%
+6.90%

More News

Read More
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
From Merck & Co., Inc.
Via Business Wire
Is Summit Therapeutics a Buy Now?
Via The Motley Fool
What's Wrong With Merck's Stock?
Via The Motley Fool
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
Why Summit Therapeutics Rocketed Over 60% Today
Via The Motley Fool
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Via Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in September
Via The Motley Fool
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Via MarketBeat
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Via MarketBeat
Exposures Product Safety
What's Going On With Merck Shares Thursday?
Via Benzinga
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Via The Motley Fool
The Smartest Dividend Stocks to Buy With $5,000 Right Now
Via The Motley Fool
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
From Merck & Co., Inc.
Via Business Wire
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
From Merck & Co., Inc.
Via Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
From Merck & Co., Inc.
Via Business Wire
2 Dividend Stocks You Can Safely Hold Through a Recession
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.